目的:观察胃舒散对慢性萎缩性胃炎患者血清胃蛋白酶原、生存质量及疗效的影响。方法:将100例慢性萎缩性胃炎患者随机分为治疗组和对照组,每组50例。对照组予西医常规疗法治疗,治疗组在对照组治疗基础上予胃舒散治疗,连续治疗4周后比较两组治疗前后血清胃蛋白酶原(PGⅠ、PGⅡ、PGⅠ/PGⅡ)、临床疗效及生存质量情况。结果:治疗组患者治疗后PGⅠ、PGⅠ/PGⅡ升高,PGⅡ降低,差异均有统计学意义(P<0.05);治疗后两组比较,治疗组PGⅠ、PGI/PGⅡ高于对照组,PGⅡ低于对照组,差异均有统计学意义(P<0.05);总有效率治疗组为72.0%,对照组为46.0%,治疗组疗效优于对照组,差异有统计学意义(P<0.05);治疗组Hp根除率高于对照组,差异有统计学意义(P<0.05);治疗组生存质量改善情况优于对照组(P<0.05)。结论:胃舒散治疗慢性萎缩性胃炎有较好疗效,能保护患者胃黏膜细胞,提高生存质量。 Objective: To observe the effect of Weishu powder on serum pepsinogen, quality of life and curative effect in patients with chronic atrophic gastritis. Methods: One hundred patients with chronic atrophic gastritis were randomly divided into treatment group and control group, 50 cases in each group. The patients in the control group were treated with conventional therapy. The patients in the treatment group were treated with Weisu Soup on the basis of the control group. After 4 weeks of continuous treatment, the serum pepsinogen (PGⅠ, PGⅡ, PGⅠ / PGⅡ) were compared before and after treatment. The clinical efficacy and survival Quality situation. Results: After treatment, the levels of PGⅠ, PGⅠ / PGⅡ and PGⅡ in the treatment group were significantly decreased (P <0.05). After treatment, the PGⅠ and PGI / PGⅡ in the treatment group were higher than those in the control group The difference was statistically significant (P <0.05). The total effective rate was 72.0% in the treatment group and 46.0% in the control group. The curative effect in the treatment group was better than that in the control group (P <0.05). The treatment group Hp eradication rate was higher than the control group, the difference was statistically significant (P <0.05); treatment group improved quality of life better than the control group (P <0.05). Conclusion: Weishuosan treatment of chronic atrophic gastritis has a good effect, can protect patients with gastric mucosal cells, improve quality of life.